

## Tyvaso® (treprostinil inhalation solution) Medication Precertification Request

Page 1 of 1

(All fields must be completed and legible for precertification review.)

**Aetna Precertification Notification** 

**Phone:** 1-866-752-7021 **FAX:** 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate:	ease indicate: Start of treatment: Start date/  Continuation of therapy, Date of last treatment / /								
D	<del></del>		Phone:			Fave			
	equested By:	Phone	:	Fax:					
A. PATIENT INFO	RMATION		1 ( )			D.O.D.			
First Name:			Last Name:	0.11		DOB:	T		
Address:		T		City:		State:	ZIP:		
Home Phone:		Work Phone:	ı	Cell Phone:	T	Email:			
Patient Current We	eight:lbs or _	kgs Patie	nt Height:inches	orcms	Allergies:				
B. INSURANCE IN	NFORMATION								
Aetna Member ID #:			Does patient have other coverage?						
Group #:			If yes, provide ID#: Carrier Name:						
Insured:	_		Insured:		_				
	□ No If yes, prov	ide ID #:	Me	dicaid: 🗌 Yes	☐ No If yes, pro	ovide ID #:			
C. PRESCRIBER	INFORMATION								
First Name:			Last Name:	1	(Check	One): 🗌 M.D. [	1	N.P.	
Address:			T	City:		State:	ZIP:		
Phone:	Fax:		St Lic #:	NPI #:	DEA #:		UPIN:		
Provider Email:			Office Contact Name:			Phone:			
Specialty (Check one):  Cardiologist Pulmonologist Other:									
D. DISPENSING F	PROVIDER/ADMINIS	STRATION INFO	RMATION						
Place of Administration:  Dispensing Provider/Pharmacy: (Patient selected choice)									
☐ Self-administer	red 🔲 Physi	cian's Office	_ · · · -			Retail Pharmacy			
Outpatient Infusion Center Phone:				☐ Specialty Pharmacy ☐ Other:					
Center Name:				Name:					
☐ Home Infusion		hone:	Address:						
Agency Name: Administration code(s) (CPT):									
Address:				TIN:PIN:					
E. PRODUCT INF				-					
		balation coluti	an) Dagg	Гиол					
Request is for: Tyvaso (treprostinil inhalation solution) Dose: Frequency:									
F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.									
Primary ICD Code:			_ Other:						
G. CLINICAL INFO	ORMATION - Requir	ed clinical inform	nation must be complete	ed in its <u>entirety</u> fo	or all precertificat	ion requests.			
For Initiation Requ	ests (clinical docum	entation required	<u>:(k</u>						
			or in consultation with a		ardiologist?				
Please indicate the World Health Organization (WHO) classification of pulmonary hypertension:									
Select one: 1 1 2 3 4 5									
☐ Yes ☐ No Does the patient have pulmonary hypertension associated with interstitial lung disease? ☐ Yes ☐ No Has PH been confirmed by right heart catheterization?									
Yes No list the patient an infant less than one year of age?									
Yes No Has Doppler echocardiogram been performed to confirm diagnosis?									
Please indicate the pretreatment mean pulmonary arterial pressure (mPAP) at rest: 🗌 less than or equal to 20mmHg 🗎 greater than 20mmHg									
Please indicate the pretreatment pulmonary capillary wedge pressure (PCWP):  less than or equal to 15 mmHg  greater than 15 mmHg  Please indicate the pretreatment pulmonary vascular resistance (PVR):  less than 3 Wood units  greater than or equal to 3 Wood units									
				VR): ∐ less than 3	3 Wood units □	greater than or e	qual to 3 W	ood units	
	Requests (clinical do								
☐ Yes ☐ No Is the requested medication prescribed by or in consultation with a pulmonologist or cardiologist? ☐ Yes ☐ No Is the patient experiencing benefit from therapy as evidenced by disease stability or disease improvement?									
		g benefit from the	erapy as evidenced by dis	sease stability or d	isease improveme	ent <i>!</i>			
H. ACKNOWLED	GEMIENT								
							e:/		
			tion of coverage of a m formation or conceals r						

insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.